For its leptomeningeal cancer drug, Plus Therapeutics found the FDA receptive to clinical trial endpoints beyond overall survival. The agency was open to "compartmental based endpoints" measuring efficacy within the targeted CNS area—a significant regulatory shift for non-systemic treatments with no established approval pathway.

The current pace of innovation in CLL treatment means new options become available faster than long-term clinical trials can conclude. This creates a critical need for more efficient trial designs and validated intermediate endpoints that can provide reliable answers sooner.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

For its alpha-1 antitrypsin deficiency program, Beam aligned with the FDA on an accelerated approval pathway based on a surrogate endpoint: restored alpha-1 protein levels. This strategy allows for faster market entry, with a longer-term confirmatory trial measuring clinical outcomes like lung and liver function running in parallel.

Recognizing that eye diseases are multifactorial, the company's research team is developing bisistronic vectors. This approach packages two different transgenes into a single AAV vector, allowing a single gene therapy product to address multiple disease pathways simultaneously, a significant advancement over single-target therapies.

To ensure patients have active disease progression and increase the likelihood of demonstrating a treatment effect, the company mandates a six-month monitoring period before intervention. This filters out slow-progressing patients where a positive outcome would be difficult to prove, thereby de-risking the clinical trial.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

The company's clinical trials go beyond standard pain scores to track improvements in function, sleep, and patient satisfaction. Demonstrating that patients can climb stairs, drive, and sleep better provides a more compelling value proposition for a faster return to normal life, resonating with patients, surgeons, and payers alike.

Ocular Therapeutix's trial prioritized a primary endpoint designed to satisfy FDA requirements for a superiority label—a key regulatory win. However, the CEO stresses that clinicians use different metrics like OCT fluid, where their drug "easily beat Eylea." This highlights a crucial strategy: separate the endpoint needed for approval from the data that drives physician adoption.